Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients Rosa F. Yeh,

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning Jamie H. Zao, Tal Schechter, Wenchao Jessica.

Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Rakesh K. Goyal, Kelong Han, Donna A. Wall, Michael A

How to Treat MDS without Stem Cell Transplantation

Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies L. Lee Dupuis, Cathryn Sibbald,

Vaccination of Children following Allogeneic Stem Cell Transplantation

Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide Paul Shaughnessy,

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Sabina Kersting, Leo F. Verdonck

Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

High-Dose Weekly AmBisome Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study Parinda.

Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning Jamie H. Zao, Tal Schechter, Wenchao Jessica.

Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation Cara L. McDermott, Brenda M. Sandmaier, Barry.

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation Walter J.F.M.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Pharmacokinetics of Mycophenolic Acid Administered 3 Times Daily after Hematopoietic Stem Cell Transplantation with Reduced-Intensity Regimen Bernard.

B Cells and Transplantation: An Educational Resource

Kasiani C. Myers, Stella M. Davies

Fluconazole Coadministration Concurrent with Cyclophosphamide Conditioning May Reduce Regimen-Related Toxicity Postmyeloablative Hematopoietic Cell Transplantation

Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K

Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Prevalence of Intracellular Galectin-1-Expressing Lymphocytes in Umbilical Cord Blood in Comparison with Adult Peripheral Blood Szonja Kollár, Noémi.

Hematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34+ and CD8+ Cell Doses Seitaro Terakura, Eiichi.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional,

Clinical Application of the Dried Blood Spot Method in the Measurement of Blood Busulfan Concentration Kana Matsumoto, Naoyuki Uchida, Amane Sakurai,

Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin

The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients Marilyn J. Hammer, Corey Casper, Ted A. Gooley,

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group Amber B. Clemmons,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J

Pauline Damien, David S. Allan

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Pharmacoeconomic Analysis and Clinical Outcomes of Staggered PK-Based Busulfan Dosing during Myeloablative Conditioning for Allogeneic Stem Cell Transplant.

Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation Radojka M. Savic, Morton.

Blood and Marrow Transplant Handbook

Linearity and Stability of Intravenous Busulfan Pharmacokinetics and the Role of Glutathione in Busulfan Elimination Shlomo Almog, Daniel Kurnik, Avichai.

Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem.

Pharmacological Immunosuppression Reduces But Does Not Eliminate the Need for Total-Body Irradiation in Nonmyeloablative Conditioning Regimens for Hematopoietic.

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Optimal Donor Selection: Beyond HLA

Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation L. Lee Dupuis,

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients Rosa F. Yeh, Matthew A. Pawlikowski, David K. Blough, George B. McDonald, Paul V. O’Donnell, Andrew Rezvani, H. Joachim Deeg, Jeannine S. McCune Biology of Blood and Marrow Transplantation Volume 18, Issue 2, Pages 265-272 (February 2012) DOI: 10.1016/j.bbmt.2011.06.013 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Median daily i.v. busulfan clearance (mL/min/kg of AIBW) after doses 1, 2, and 3. Legend: Box and whiskers represent 25th and 75th percentiles (interquartile range) and 10th and 90th percentiles, respectively. AIBW, adjusted ideal body weight. Biology of Blood and Marrow Transplantation 2012 18, 265-272DOI: (10.1016/j.bbmt.2011.06.013) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Minimal interdose variability in daily i.v. busulfan clearance by conditioning regimen. Interdose busulfan clearance (mL/min/kg of AIBW) calculated as [(CLdose2 – CLdose 1)/CLdose1] × 100% (see Statistical Methods for additional details). Box and whiskers represent 25th and 75th percentiles (interquartile range) and 10th and 90th percentiles, respectively. TBU, targeted busulfan; AIBW, adjusted ideal body weight. (A) CY followed by TBU. P > .36 for all comparisons. (B) Fludarabine followed by TBU. (C) TBU concurrent with fludarabine. Biology of Blood and Marrow Transplantation 2012 18, 265-272DOI: (10.1016/j.bbmt.2011.06.013) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Feasibility of shorter pharmacokinetic sampling intervals to estimate Css. Css, concentration at steady-state. Percent difference in Css estimated from pharmacokinetic samples obtained over 24 hours (gold standard) compared with that from shorter time intervals (ie, 11, 8, and 6 hours). First sample obtained at the end of a 3-hour infusion. Css estimated using either 1-compartment model or noncompartmental analysis. Box and whiskers represent 25th and 75th percentiles (interquartile range) and 10th and 90th percentiles, respectively. Biology of Blood and Marrow Transplantation 2012 18, 265-272DOI: (10.1016/j.bbmt.2011.06.013) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions